BridgeBio Pharma, Inc.

https://www.bridgebio.com

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company dedicated to discovering, developing, testing, and delivering transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Founded in 2015 and headquartered in Palo Alto, California, the company's mission is to bridge the gap between scientific advancements and effective therapies, addressing significant unmet medical needs, particularly in rare diseases.

BridgeBio focuses on a diverse pipeline spanning Mendelian disorders, precision oncology, and gene therapy. Key products and investigational therapies include Attruby (acoramidis) for transthyretin amyloid cardiomyopathy (ATTR-CM), and NULIBRY (fosdenopterin) for molybdenum cofactor deficiency (MoCD) Type A, both of which are approved. The company's late-stage pipeline features BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), for which an NDA was submitted in March 2026, encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1) with an NDA planned for the first half of 2026, and infigratinib for achondroplasia and hypochondroplasia. The company operates on a hub-and-spoke model, allowing autonomous teams to focus on specific conditions while leveraging central clinical, regulatory, and commercial capabilities.

Led by co-founder and CEO Neil Kumar, Ph.D., BridgeBio has demonstrated strong market positioning, with Attruby sales exceeding projections in 2025, reaching $362 million. The company reported full-year 2025 revenues of $502.1 million and is scheduled to release its first quarter 2026 financial results on May 7, 2026. In 2024, BridgeBio strategically spun out its KRAS-focused cancer portfolio into BridgeBio Oncology Therapeutics and early-stage assets into GondolaBio, further solidifying its focus on a robust and diversified pipeline.

Latest updates

BridgeBio Launches Awareness Campaign for ATTR-CM, Enlists Freeman, White

Event summary

  • BridgeBio Pharma launched a national health education campaign, 'Don’t Pass On Your Heart Health,' to raise awareness of ATTR-CM.
  • The campaign features actor Morgan Freeman and sports business executive Howard H. White, who shared personal experiences with delayed diagnosis.
  • ATTR-CM is often misdiagnosed as other forms of heart failure or aging, particularly impacting women over 55 and Black communities.
  • Attruby® (acoramidis), BridgeBio’s treatment for ATTR-CM, demonstrated a 50% reduction in cardiovascular-related hospitalizations in a Phase 3 study.

The big picture

BridgeBio’s campaign highlights the ongoing challenge of rare disease awareness and diagnosis, particularly in conditions like ATTR-CM where symptoms mimic more common ailments. The use of high-profile advocates underscores the growing recognition of patient advocacy's role in driving adoption of specialized therapies. This initiative also speaks to the broader trend of pharmaceutical companies investing in direct-to-consumer education to address diagnostic delays and improve patient outcomes.

What we're watching

Adoption Rate
The success of the campaign hinges on whether it leads to increased patient and physician awareness, ultimately driving earlier diagnosis and treatment with Attruby.
Market Penetration
Given the disproportionate impact on Black communities, BridgeBio’s ability to effectively reach and engage this demographic will be crucial for maximizing market penetration.
Competitive Landscape
The emergence of other ATTR-CM therapies will likely intensify competition, requiring BridgeBio to continually demonstrate Attruby’s value proposition and maintain market share.

Acoramidis Shows Sustained Mortality Benefit in ATTR-CM Trial

Event summary

  • Long-term data from the ATTRibute-CM trial demonstrated a 44.7% reduction in all-cause mortality (ACM) and a 49.3% reduction in cardiovascular mortality (CVM) through Month 54 (p<0.0001).
  • Acoramidis mitigated the rise in NT-proBNP through Month 54 to a greater extent than observed with previous disease-modifying treatments.
  • Treatment with acoramidis stabilized and maintained heart failure-related quality of life scores (KCCQ-OS) through Month 54.
  • The findings were presented at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo and simultaneously published in JAMA Cardiology.

The big picture

ATTR-CM represents a significant unmet medical need, and while several therapies have emerged, patient outcomes remain suboptimal. BridgeBio’s acoramidis data suggest a meaningful improvement in survival and quality of life, but the real-world survey data highlights a gap between available treatment and patient access. The long-term data strengthens the company’s position in a competitive market, but sustained adoption will require addressing physician and patient concerns.

What we're watching

Commercialization
The real-world survey data highlighting physician dissatisfaction and patient undertreatment suggests challenges in acoramidis adoption despite efficacy, requiring BridgeBio to address awareness and access barriers.
Competitive Landscape
Given the emergence of other ATTR-CM therapies, the sustainability of acoramidis’ market share will depend on continued demonstration of superior long-term outcomes and a favorable cost-benefit profile.
Regulatory Scrutiny
Further data releases and post-market surveillance will be critical to maintaining regulatory approval and addressing any potential long-term safety concerns, particularly given the relatively high discontinuation rate due to adverse events.

BridgeBio Submits NDA for LGMD2I/R9 Therapy, Eyes First-in-Class Approval

Event summary

  • BridgeBio submitted a New Drug Application (NDA) to the FDA for BBP-418, an oral therapy targeting limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
  • Interim Phase 3 FORTIFY data demonstrated statistically significant and clinically meaningful improvements in ambulation and pulmonary function.
  • BridgeBio anticipates FDA approval and a U.S. launch in late 2026/early 2027.
  • If approved, BBP-418 would be the first therapy for LGMD2I/R9 and potentially the first approved treatment for any form of LGMD.

The big picture

BridgeBio's NDA submission highlights the growing focus on developing therapies for rare genetic diseases, a segment often underserved due to commercial challenges. The potential approval of BBP-418 would represent a significant breakthrough for patients with LGMD2I/R9 and could pave the way for treatments targeting other forms of LGMD, a market with limited therapeutic options. BridgeBio's decentralized model, designed for speed and precision, will be crucial in navigating the regulatory and commercial hurdles ahead.

What we're watching

Regulatory Pathway
The FDA’s decision on Priority Review designation will significantly impact the approval timeline and market launch of BBP-418, given the unmet need and Rare Pediatric Disease designation.
Commercialization
BridgeBio’s ability to establish a pricing and reimbursement strategy for BBP-418 will be critical, given the small patient population and potential for high treatment costs.
Expansion
The success of BBP-418 in LGMD2I/R9 will likely influence BridgeBio’s strategy for expanding the therapy’s use to other LGMD subtypes and age groups, as indicated in the press release.

BridgeBio Data to Highlight Long-Term Acoramidis Benefit in ATTR-CM

Event summary

  • BridgeBio will present long-term efficacy and safety data for acoramidis (ATTRibute-CM) at the ACC Annual Scientific Sessions on March 30, 2026.
  • The oral presentation will focus on survival benefits and disease stabilization in patients with ATTR-CM.
  • Three additional posters will detail data on serum transthyretin concentrations, KCCQ-OS scores, and the association between sTTR increase and health status.
  • ATTRibute™ (acoramidis) is indicated for the treatment of ATTR-CM in adults to reduce cardiovascular death and hospitalization.

The big picture

BridgeBio's ATTRibute-CM represents a significant opportunity in the emerging ATTR-CM treatment market, which is driven by increasing awareness and diagnostic capabilities. The long-term data release is a key milestone for the company, as it seeks to establish a durable competitive advantage and expand its commercial footprint. Success hinges on demonstrating sustained efficacy and a manageable safety profile, particularly given the relatively high cost of the therapy.

What we're watching

Clinical Validation
The long-term data presented at ACC will be critical in solidifying the clinical benefit of acoramidis beyond the initial Phase 3 trial, influencing physician adoption and payer coverage decisions.
Competitive Landscape
The presentation's findings will be scrutinized by competitors developing alternative ATTR-CM therapies, potentially impacting BridgeBio's market share and pricing power.
Adverse Event Profile
Continued monitoring of adverse events, particularly diarrhea and upper abdominal pain, will be essential to assess the long-term safety and tolerability of acoramidis in a broader patient population.

BridgeBio Phase 3 Data Suggests First-in-Class LGMD2I/R9 Therapy

Event summary

  • Phase 3 FORTIFY interim analysis data for BBP-418 demonstrated efficacy across key clinical endpoints and subgroups in individuals with LGMD2I/R9.
  • Early separation from placebo was observed in the 100MTT, with improvements in ambulation seen as early as three months.
  • BridgeBio intends to submit an NDA to the FDA in the first half of 2026, targeting a late 2026/early 2027 launch.
  • The therapy could be the first approved treatment for LGMD2I/R9 and potentially the first for any form of LGMD.

The big picture

The positive FORTIFY data represent a significant advancement in the treatment of LGMD2I/R9, a debilitating and previously untreatable rare genetic disorder. BridgeBio's success underscores the growing focus on developing therapies for underserved patient populations with genetic conditions, a trend driven by scientific advancements and increasing regulatory incentives. The potential approval of BBP-418 could establish a new precedent for therapeutic intervention in the broader landscape of limb-girdle muscular dystrophies.

What we're watching

Regulatory Path
The FDA's acceptance and potential expedited review pathway for BBP-418 will be critical, given the unmet need and potential first-in-class status, and the company's stated intention to engage regulators.
Commercialization
The success of the anticipated 2026/2027 launch will depend on BridgeBio's ability to effectively reach and serve a small, geographically dispersed patient population with a complex diagnostic journey.
Expansion
BridgeBio's plans to expand clinical trials to younger patients and other LGMD subtypes will test the breadth of BBP-418's efficacy and the scalability of their development program.

BridgeBio Data Shows Efficacy in LGMD2I/R9 Trial, Bolstering Pipeline

Event summary

  • BridgeBio will present interim data from the Phase 3 FORTIFY trial of BBP-418 for LGMD2I/R9 at the MDA Clinical & Scientific Conference on March 11, 2026.
  • The presentation indicates the trial met its efficacy endpoints, a significant development for the treatment of this rare genetic condition.
  • Yale School of Medicine collaborators will also present data on a high-throughput assay for ribitol response and four related posters.
  • Katherine Mathews, M.D. from the University of Iowa, will lead the oral presentation on the FORTIFY trial data.

The big picture

LGMD2I/R9 represents a significant unmet medical need, and successful therapies in this space can command premium pricing. BridgeBio’s hub-and-spoke model aims to capitalize on this, but relies on consistent clinical successes to maintain investor enthusiasm and funding for its diverse pipeline. The FORTIFY trial data is a crucial inflection point for the company’s strategy and valuation.

What we're watching

Regulatory Approval
The strength of the presented data will heavily influence the likelihood and timeline of regulatory approval for BBP-418, a critical factor for BridgeBio's future revenue projections.
Market Adoption
The real-world insights poster will provide early indications of potential patient uptake and reimbursement challenges, which could impact the commercial viability of the therapy.
Pipeline Expansion
BridgeBio's decentralized model relies on consistent success; the FORTIFY trial’s outcome will shape investor confidence in the company’s broader pipeline strategy for rare genetic conditions.

BridgeBio Advances Pipeline, Bolsters Finances Amidst Accelerating Drug Development

Event summary

  • BridgeBio reported $502.1 million in net revenues for full-year 2025, driven primarily by $362.4 million in Attruby product revenue.
  • The company achieved positive Phase 3 trial readouts for three pipeline programs: BBP-418 (LGMD2I/R9), encaleret (ADH1), and infigratinib (achondroplasia).
  • BridgeBio issued $632.5 million in convertible notes in January 2026, bolstering its cash position to $587.5 million.
  • Attruby continues to demonstrate strong commercial performance, with 7,804 unique patient prescriptions written by February 20, 2026, representing 35% quarter-over-quarter growth.

The big picture

BridgeBio’s rapid pipeline advancement and strong commercial performance with Attruby underscore the potential of its unique, decentralized drug development model. The company’s ability to consistently deliver positive Phase 3 data, coupled with its recent capital raise, positions it to capitalize on the growing demand for therapies targeting rare genetic conditions, a market increasingly attracting investment despite inherent development risks. However, the company's reliance on a concentrated portfolio of late-stage assets creates a significant execution risk should any of these programs fail to achieve regulatory approval.

What we're watching

Regulatory Risk
The FDA’s response to the NDA submissions for BBP-418 and encaleret will be critical, as a rejection or significant delay could impact timelines and investor sentiment.
Commercial Execution
The success of the BBP-418 and encaleret launches will depend on effective sales and marketing strategies, and the ability to capture market share from existing therapies.
Pipeline Expansion
The progress of earlier-stage programs, particularly the Depleter for ATTR-CM, will be key to BridgeBio’s long-term growth trajectory and ability to sustain its hub-and-spoke model.

BridgeBio's Infigratinib Data Show First Statistically Significant Body Proportionality Improvement in Achondroplasia

Event summary

  • BridgeBio's Phase 3 PROPEL 3 trial demonstrated a statistically significant improvement in annualized height velocity (AHV) with infigratinib, showing a mean treatment difference of +2.10 cm/year against placebo (p<0.0001).
  • The trial also achieved the first statistically significant improvement in body proportionality in children under 8 years old (LS mean treatment difference of -0.05, p<0.05) – a key secondary endpoint.
  • BridgeBio plans to submit an NDA and MAA in the second half of 2026 and will accelerate development for hypochondroplasia.
  • Infigratinib was well-tolerated, with no discontinuations or serious adverse events related to the drug, and only a 4% incidence of mild, transient hyperphosphatemia.

The big picture

BridgeBio's success with infigratinib represents a significant advancement in treating achondroplasia, a rare genetic disorder with a substantial unmet need. The demonstration of improved body proportionality, beyond just height, positions infigratinib as a potentially transformative therapy. This achievement underscores the growing focus on addressing the broader health and functional impacts of rare diseases, rather than solely focusing on symptomatic relief.

What we're watching

Regulatory Approval
The FDA and EMA review timelines will be critical; a fast-track approval could significantly boost BridgeBio's valuation, while delays could raise concerns about efficacy or safety.
Market Adoption
The uptake of an oral therapy versus existing injectable treatments will depend on physician and patient preferences, and BridgeBio's ability to effectively communicate the body proportionality benefit.
Expansion Potential
The success of the hypochondroplasia development program will hinge on whether infigratinib's FGFR3-targeting mechanism proves effective in this related, but distinct, skeletal dysplasia.

BridgeBio Extends Debt, Repurchases Shares in Complex Financing

Event summary

  • BridgeBio priced $550 million in convertible senior notes due 2033 at a 0.75% interest rate, with an initial conversion price of approximately $110.58 per share.
  • The proceeds will primarily be used to repurchase or repay existing $2027 convertible senior notes.
  • BridgeBio simultaneously executed share repurchases of approximately 1.1 million shares at the prevailing market price, totaling $82.5 million.
  • The offering includes an option for initial purchasers to buy an additional $82.5 million in notes.

The big picture

BridgeBio’s move to extend its debt maturity and repurchase shares signals a strategic shift towards optimizing its capital structure. The low interest rate on the new notes, coupled with the share buyback, suggests a belief that the company’s stock is undervalued and that it can manage its debt obligations effectively. This complex financing underscores the ongoing trend of biopharma companies utilizing convertible notes to balance fundraising needs with potential dilution concerns.

What we're watching

Conversion Dynamics
The success of this financing hinges on BridgeBio’s ability to maintain a share price above the conversion threshold to avoid dilutive share issuance, which could pressure future capital raises.
Debt Management
The extent to which BridgeBio repays its 2027 notes with the new proceeds will be a key indicator of its financial flexibility and commitment to reducing its debt burden.
Shareholder Perception
Market reaction to the share repurchase program and the overall financing structure will reveal investor sentiment regarding BridgeBio’s valuation and capital allocation strategy.

BridgeBio Prefunds 2027 Debt with $550M Convertible Note Offering

Event summary

  • BridgeBio announced a proposed $550 million offering of convertible senior notes due 2033, with an option for an additional $82.5 million.
  • Proceeds will primarily be used to repurchase or repay BridgeBio’s existing 2.50% convertible senior notes due 2027.
  • BridgeBio intends to use $82.5 million in cash to repurchase shares from purchasers of the new notes.
  • The notes will be convertible into cash, common stock, or a combination, with conversion terms subject to change.
  • The company may redeem the notes starting February 6, 2030, if the stock price exceeds 130% of the conversion price.

The big picture

BridgeBio's move reflects a common strategy among growth-stage biopharma companies: extending debt maturities and managing dilution through convertible instruments. The prefunding of the 2027 repayment suggests a desire to proactively address upcoming obligations and potentially benefit from favorable market conditions. This transaction, while seemingly straightforward, carries implications for BridgeBio's cost of capital and shareholder dilution profile.

What we're watching

Conversion Dynamics
The ultimate conversion rate of the new notes will be a key indicator of investor sentiment regarding BridgeBio’s future stock performance and potential dilution.
Share Price Trajectory
The share repurchase program’s impact on the stock price, and whether it can sustain a level that triggers the note redemption clause, warrants close observation.
Debt Refinancing
How effectively BridgeBio manages the transition from the 2027 notes to the 2033 notes will reflect on its overall financial flexibility and ability to navigate future capital needs.

BridgeBio Revenue Surges, Eyes ATTR Reversal with New Antibody Program

Event summary

  • BridgeBio reported preliminary Q4 and full-year 2025 net Attruby product revenue of $146.0 million and $362.4 million, respectively.
  • Attruby has achieved rapid adoption, with 6,629 unique patient prescriptions written by 1,632 prescribers as of December 31, 2025.
  • BridgeBio announced a new TTR amyloid depleter antibody program targeting ATTR-CM disease reversal, with clinic entry expected between 2027-2028.
  • The FDA recommended pursuing traditional approval for BBP-418 (LGMD2I/R9), with an NDA submission planned for the first half of 2026.
  • BridgeBio holds approximately $587.5 million in cash, cash equivalents, and marketable securities.

The big picture

BridgeBio's strong Attruby performance and aggressive pipeline expansion demonstrate a strategy of rapid drug development and commercialization within the genetic disease space. The announcement of a disease-reversing antibody program signals a shift towards more ambitious therapeutic goals, potentially disrupting the ATTR-CM treatment landscape. The company's substantial cash reserves provide flexibility to fund these initiatives and potentially launch multiple new therapies, but also increase pressure to deliver on ambitious timelines.

What we're watching

Clinical Timelines
The success of the new TTR amyloid depleter antibody program hinges on its ability to meet the projected 2027-2028 clinic entry timeline, which will dictate the potential for disease reversal and a significant expansion of BridgeBio's ATTR-CM market share.
Regulatory Risk
While the FDA’s recommendation for traditional approval of BBP-418 is positive, the ultimate approval and subsequent commercial success remain contingent on favorable review of the full NDA submission and data.
Commercial Momentum
Attruby’s current rapid adoption rate may not be sustainable, and the company must demonstrate continued physician and patient buy-in to maintain its position as the first-choice therapy for ATTR-CM.

BridgeBio CEO to Present at J.P. Morgan Healthcare Conference

Event summary

  • BridgeBio CEO Neil Kumar will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
  • The presentation will be webcast live and replayed on BridgeBio's investor relations website.
  • BridgeBio was founded in 2015 and focuses on developing treatments for genetic diseases.
  • The company's pipeline includes programs ranging from early science to advanced clinical trials.

The big picture

BridgeBio’s participation in the J.P. Morgan Healthcare Conference underscores the continued investor interest in companies targeting genetic diseases, a sector experiencing increasing R&D investment. The conference provides a key platform for BridgeBio to communicate its strategy and pipeline progress to a broad audience of institutional investors. The company’s unique model of acquiring and developing multiple genetic therapies presents both opportunities and challenges in a competitive landscape.

What we're watching

Pipeline Progress
The content of Kumar's presentation will likely reveal the current status of BridgeBio's development programs, and any updates could significantly impact investor sentiment.
Growth Strategy
Given BridgeBio’s unique company structure and focus on genetic diseases, the presentation may offer insights into their acquisition and development strategy, which will be crucial for long-term growth.
Market Reception
The level of investor engagement and questions during and after the webcast will provide a gauge of market confidence in BridgeBio’s approach and pipeline.

BridgeBio to Detail Achondroplasia Trial Data in Investor Webinar

Event summary

  • BridgeBio will host an investor webinar on January 9, 2026, at 8:00 am ET.
  • The webinar will feature Janet Legare, M.D., a leading expert in achondroplasia and investigator in the PROPEL 3 trial.
  • Dr. Legare will discuss the pathophysiology of achondroplasia and the rationale for infigratinib treatment.
  • BridgeBio’s skeletal dysplasia program team will review ongoing clinical development and the Phase 3 PROPEL 3 study.
  • Topline results from the PROPEL 3 trial are expected in Q1 2026.

The big picture

BridgeBio’s focus on achondroplasia, a rare genetic disorder, aligns with the broader trend of biopharmaceutical companies targeting niche patient populations for accelerated drug approvals and premium pricing. The webinar highlights the company’s commitment to advancing infigratinib, a potential first-in-class treatment, and underscores the importance of key opinion leader engagement in securing market access for rare disease therapies. The success of PROPEL 3 will be a key determinant of investor confidence in BridgeBio’s pipeline and overall strategy.

What we're watching

Clinical Data
The webinar’s focus on PROPEL 3 suggests BridgeBio is eager to preemptively manage expectations surrounding the topline results, potentially indicating concerns about the trial’s outcome.
Key Opinion Leader
The prominent role of Dr. Legare, with her extensive network and affiliations, signals an effort to bolster credibility and influence physician adoption of infigratinib, should the trial succeed.
Commercialization
Given the relatively small patient population affected by achondroplasia, BridgeBio’s ability to demonstrate a clear return on investment for infigratinib will be critical to justifying the program’s ongoing expense.
CID: 514